Oxurion Releases Financial Update for First Half of 2026

Leuven, Belgium – Oxurion NV (Euronext Brussels: OXUR) has announced its financial results and business update for the first half of 2026, ending June 30. The detailed report can be accessed through the company's website.

The update provides significant insights into Oxurion's progress and operational strategies. Despite the ongoing challenges in the pharmaceutical and biotech industries, Oxurion focuses on enhancing its clinical research and software capabilities. The firm aims to support sponsors in pharmaceuticals, biotechnology, and medical devices through innovation and data.

Oxurion advises investors of the inherent uncertainties tied to its forward-looking statements, necessitating caution. Comprehensive risk information is available in their annual report. No securities of Oxurion can be traded in the U.S. without compliance with the U.S. Securities Act of 1933.